Trial Profile
A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and tolerability of a 14 day treatment course of GW493838 50mg compared to placebo in subjects with peripheral neuropathic pain
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2023
Price :
$35
*
At a glance
- Drugs GW 493838 (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 05 Nov 2006 New trial record.